NCT03853044UNKNOWNanonymous

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Sponsor

Source record

Ruijin Hospital

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Indication / condition

AI-normalized

Angioimmunoblastic T-cell Lymphoma

Intervention

Source record

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Source & freshness

Source record

NCT ID

NCT03853044

Original source

ClinicalTrials.gov

Source last updated

Apr 20, 2022

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03853044

Title

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Sponsor

Ruijin Hospital

Status

UNKNOWN

Phase

PHASE2

Condition raw

Angioimmunoblastic T-cell Lymphoma

Condition normalized

Angioimmunoblastic T-cell Lymphoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Target normalized

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Interventions

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Public preview

Source record

This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03853044

Status

UNKNOWN

Phase

PHASE2

Sponsor

Ruijin Hospital

Executive brief

Investment-Ready Snapshot

This is a single-arm, open-label phase 2study of Chidamide in combination with CHOP in the treatment of subjects with untreated angioimmunoblastic T cell lymphoma.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 20, 2022

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03853044

Indication

Angioimmunoblastic T-cell Lymphoma

Modality

small molecule

Target

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Intervention

Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.